5Bretti S, Manzin E, Loddoc, et al. Gemeitabine plus cisplatin in the tretment of patients with advanced non- small- cell lung caneer : a phage II atudy [J]. Anticancer Res, 2002,22 (5) : 3039 - 3043. 被引量：1
二级参考文献11
1[1]Ray mod E,Chaney S,Taama A,et al.Oxaliplatin:A review of preclinical and clinical studies[J].Ann Oncol,1988,9(7):1053-1071. 被引量：1
2[2]Barton BM.Gemcitabine:a pharmacologic and clinical overview[J].Cancer,1999,22(2):176. 被引量：1
3[3]Fraciosi V,Barbieri R,Aitini E,et al,Gemcitabine and Oxalipatin:a safe and active regimen in poor pregnosis advanced non-small-cell lung cancer patients[J].Lung Cancer,2003,41(1):101-106. 被引量：1
4[4]Bretti S,Manzin E,Loddo C,et al.Gemcitabine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer:a phase II study[J].Anticancer Res,2002,22(5):3039-3043. 被引量：1
5[5]Extra J,Marty M,Brionza S,Pharmackinetics and safely profile of oxaliplatin[J].Semin Oncol,1998,25(suppl5):13-22. 被引量：1
6Sandier AB, Nemunaitis J, Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer [J]. J Clin Oncol, 2000, 18 (1): 122-130. 被引量：1
7Monnet I,Brienza S,Hugret F,et al. Phase Ⅱ study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques [J]. Eur J Cancer, 1998,34(7) : 1124-1127. 被引量：1
8Faivre S, Raymond E, Woynarowski JM, et al. Supraadditive effect of 2', 2'-difluorodeoxycytidine ( gemcitabine ) human cancer Pharmacol, 1999 in combination with oxaliplatin in cell lines [J ]. Cancer Chemother Pharmacol, 1999,44(2) : 117- 123. 被引量：1
9Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase Ⅱ clinical trial with 5- fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer [J]. Cancer, 1992,69 (4) : 893 - 900. 被引量：1
10Crino L, Novello S, Marinis DF, et al. Gemcitabinoxaliplatin (GEMOX) chemotherapy as first-line treatment in advanced non-small ceil lung cancer: preliminary results of a multicenter phase Ⅱ study [C]. ASCO, 2003. 被引量：1
4Pallares C, Capdevila J, Paredes A, et al. Induction chemotherapywith paclitaxel plus carboplation followde by paxclitaxel with concur- rent radiotherapy in Ill B non-small-cell lung cancer (NSCLC) pa- tients: a phase H trial[J]. Lung Cancer, 2007, 58(2) :238 245. 被引量：1
5Ang KK,Andratschke N, Milas L. Epidermal growth factor re- ceptor and response of head-and-neck carcinoma to therapy[J]. Int J Radiat Oncol Biol Phys, 2004, 58(3) : 959-965. 被引量：1
6Tiseo M, Cridelli C, Cascinu S, et al. An expanded access pro- gram of erlotinib(Tarceva) in patients with advanced non-small cell lung cancer (NSCLC)=Date report form ltaly[J]. Lung Cancer,2009, 64(2) ~199. 被引量：1
7Videtic GM, Rice TW, Murthy S, et al. Phase I/]1 trial of the addition of erlotinibto pre2 and postoperative chemotherapy/ hyperfractionated radiotherapy, and as maintenance, for resect- able mediastinoscopy definedstage Ill non-small cell lung cancer (NSCLC) : Report on the phase l] component [J]. J Thorac On- col, 2009, 4(Suppl 1): 30-36. 被引量：1
8Shepherd FA, Rodrigues Pereira J, Ciuleaun T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 2005, 353(2)=123-132. 被引量：1
9Perez-Soler R, Chaehoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with nowsmall- cell lung cancer[J]. J Clin Oncol, 2004,22(16):3238- 3247. 被引量：1
